Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Adenocarcinoma of Lung 5Melanoma 3Neoplasm Metastasis 2Noonan Syndrome 6 1Neoplasms 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Kidney Neoplasms 1Carcinoma 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × capmatinib × Clear all
NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Novartis

Phase 2 Completed
373 enrolled 34 charts 2 FDA
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT03240393 2018-07-26

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Novartis

Phase 2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡